332 related articles for article (PubMed ID: 24694321)
1. Retinoid receptor signaling and autophagy in acute promyelocytic leukemia.
Orfali N; McKenna SL; Cahill MR; Gudas LJ; Mongan NP
Exp Cell Res; 2014 May; 324(1):1-12. PubMed ID: 24694321
[TBL] [Abstract][Full Text] [Related]
2. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
Orfali N; O'Donovan TR; Cahill MR; Benjamin D; Nanus DM; McKenna SL; Gudas LJ; Mongan NP
Eur J Haematol; 2020 Mar; 104(3):236-250. PubMed ID: 31811682
[TBL] [Abstract][Full Text] [Related]
3. Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia.
Moosavi MA; Djavaheri-Mergny M
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330838
[TBL] [Abstract][Full Text] [Related]
4. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
5. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.
Benedetti L; Grignani F; Scicchitano BM; Jetten AM; Diverio D; Lo Coco F; Avvisati G; Gambacorti-Passerini C; Adamo S; Levin AA; Pelicci PG; Nervi C
Blood; 1996 Mar; 87(5):1939-50. PubMed ID: 8634442
[TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Nitto T; Sawaki K
J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
[TBL] [Abstract][Full Text] [Related]
8. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.
Dong S; Tweardy DJ
Blood; 2002 Apr; 99(8):2637-46. PubMed ID: 11929748
[TBL] [Abstract][Full Text] [Related]
9. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro.
Shiohara M; Dawson MI; Hobbs PD; Sawai N; Higuchi T; Koike K; Komiyama A; Koeffler HP
Blood; 1999 Mar; 93(6):2057-66. PubMed ID: 10068679
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
11. [Mechanism of action of retinoids in a new therapeutic approach to acute promyelocytic leukemia].
Cornic M; Guidez F; Delva L; Agadir A; Degos L; Chomienne C
Bull Cancer; 1992; 79(7):697-704. PubMed ID: 1334741
[TBL] [Abstract][Full Text] [Related]
12. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias.
Yousefnia S
Cell Biol Int; 2021 Jun; 45(6):1148-1157. PubMed ID: 33527587
[TBL] [Abstract][Full Text] [Related]
14. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
15. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells.
Albanesi J; Noguera NI; Banella C; Colangelo T; De Marinis E; Leone S; Palumbo O; Voso MT; Ascenzi P; Nervi C; Bianchi F; di Masi A
Cells; 2020 Nov; 9(11):. PubMed ID: 33167477
[TBL] [Abstract][Full Text] [Related]
18. Retinoids in cancer chemoprevention.
Okuno M; Kojima S; Matsushima-Nishiwaki R; Tsurumi H; Muto Y; Friedman SL; Moriwaki H
Curr Cancer Drug Targets; 2004 May; 4(3):285-98. PubMed ID: 15134535
[TBL] [Abstract][Full Text] [Related]
19. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
[TBL] [Abstract][Full Text] [Related]
20. The molecular biology of acute promyelocytic leukemia.
Slack JL; Gallagher RE
Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
